Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.

Vyzula,  Rostislav; Kocáková,  Ilona; Demlová,  Regina; Kiss,  Igor; Dušek,  Ladislav; Jarkovský,  Jiří

Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	VYZULA Rostislav KOCÁKOVÁ Ilona DEMLOVÁ Regina KISS Igor DUŠEK Ladislav JARKOVSKÝ Jiří
Year of publication	2006
Type	Article in Periodical
Magazine / Source	Neoplasma
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	colorectal cancer; palliative chemotherapy; raltitrexed oxaliplatin
Description	The primary endpoint of this study was to evaluate the efficacy (objective response rate; ORR) of combined chemotherapy with raltitrexed plus oxaliplatin as second-line treatment in patients with metastatic colorectal cancer (CRC). Secondary endpoints were overall survival (OS), time to progression (TTP) and toxicity (NCI-CTC criteria). The target population were patients with metastatic colorectal adenocarcinoma who progressed after first-line chemotherapy. Treatment consisted of raltitrexed 3 mg/m(2) as a 15-minute intravenous (IV) infusion followed 45 minutes later by oxaliplatin 130 mg/m(2) IV as a 2-h infusion on Day 1, repeated every 3 weeks until further disease progression (PD), unacceptable toxicity or the decision of the patient. A total of 51 patients, all with WHO performance status 0-2 received a median of 6 treatment cycles (range 1-11). After 3 cycles, 8 of the 47 evaluable patients (17%) had experienced an ORR, 28 patients (59.6%) had experienced stable disease (SD) and 11 patients (23.4%) had PD. After 6 cycles, 1 of the 29 evaluable patients (3.5%) had an ORR, 13 patients (44.8%) had SD and 15 patients (51.7%) had PD. After a median follow-up of 48.9 weeks, median TTP was 18 weeks and median overall survival was 54.4 weeks. Treatment was well tolerated; grade 3 toxicities occurred in only 5/51 patients (9.8%). The most common toxicities were paraesthesia (62.7%), diarrhoea (23.5%), nausea (41.2%), vomiting (33.3%), hepatotoxicity (25.5%), and hematological toxicity (41.2%). In conclusion, the combination of oxaliplatin plus raltitrexed appears to be effective and well tolerated as second-line therapy in patients with disseminated CRC.